Professor of Medicine, University Tex Houston
Oncology
Dr. Jaffer A. Ajani, MD
|
|
Give Review
Dr. Jaffer A. Ajani works in the field of Oncology. He studied medicine at Indira Gandhi Medical College. He received 3 awards: "America's Top Doctors", "Top Doctors:SE Texas" and "America's Top Doctors for Cancer". Jaffer A. Ajani has written publications. He has 95 publications published with PubMed. The lastest publication is: 'A Phase I/II Study of Docetaxel, Oxaliplatin, and Fluorouracil (D-FOX) Chemotherapy in Patients With Untreated Locally Unresectable or Metastatic Adenocarcinoma of the...' Doctor Jaffer A. Ajani, MD is registered with Medicare and accepts Medicare payments.
Publications
- Survival in Patients With Esophageal AdenoCarcinoma Undergoing Trimodality Therapy Is Independent of Regional Lymph Node Location.
- Frequency of Resection After Preoperative Chemotherapy or Chemoradiotherapy for Gastric AdenoCarcinoma.
- A Phase I/II Study of Docetaxel, Oxaliplatin, and Fluorouracil (D-FOX) Chemotherapy in Patients With Untreated Locally Unresectable or Metastatic AdenoCarcinoma of the...
- The best timing for administering systemic chemotherapy in patients with locally advanced rectal Cancer.
- Quality Indicators for the Management of Barrett's Esophagus, Dysplasia, and Esophageal AdenoCarcinoma: International Consensus Recommendations from the American Gastr...
- Long-Term Survival in Patients with Gastroesophageal Junction Cancer Treated with Preoperative Therapy: Do Thoracic and Abdominal Approaches Differ?
- Current concepts and future potential in neoadjuvant chemotherapy for esophageal Cancer.
- Signatures of tumour immunity distinguish Asian and non-Asian gastric adenoCarcinomas.
- Comprehensive geriatric assessment in patients with gastric and gastroesophageal adenoCarcinoma undergoing gastrectomy.
- The Hippo coactivator YAP1 mediates EGFR overexpression and confers chemo-resistance in esophageal Cancer.
- Distribution of Resistant Esophageal AdenoCarcinoma in the Resected Specimens of Clinical Stage III Patients after Chemoradiation: Its Clinical Implications.
- Clinical Benefit and Health-Related Quality of Life Assessment in Patients Treated with Cisplatin/S-1 Versus Cisplatin/5-FU: Secondary End Point Results From the First...
- A nomogram that predicts pathologic complete response to neoadjuvant chemoradiation also predicts survival outcomes after definitive chemoradiation for esophageal Cancer.
- Geographic Distribution of Regional Metastatic Nodes Affects the Outcome of Trimodality-Eligible Patients with Esophageal AdenoCarcinoma.
- A validated miRNA profile predicts response to therapy in esophageal adenoCarcinoma.
- Medical management of gastric Cancer: A 2014 update.
- Importance of Surveillance and Success of Salvage Strategies After Definitive Chemoradiation in Patients With Esophageal Cancer.
- Epigenomic characterization of locally advanced anal Cancer: a radiation therapy oncology group 98-11 specimen study.
- Clinical Staging of Patients with Early Esophageal AdenoCarcinoma: Does FDG-PET/CT Have a Role?
- Metformin sensitizes chemotherapy by targeting Cancer stem cells and the mTOR pathway in esophageal Cancer.
- Potentially Functional Variants in the Core Nucleotide Excision Repair Genes Predict Survival in Japanese Gastric Cancer Patients.
- Signet Ring Cells in Esophageal Adenocarcinoma Predict Poor Response to Preoperative Chemoradiation.
- Hippo coactivator YAP1 upregulates SOX9 and endows stem-like properties to esophageal Cancer cells.
- Genetic and intermediate phenotypic susceptibility markers of gastric Cancer in Hispanic Americans: A case-control study.
- Reply to R. Gertler et al.
- Genetic polymorphisms in the microRNA binding-sites of the thymidylate synthase gene predict risk and survival in gastric Cancer.
- Anti-angiogenic agent ramucirumab: meaningful or marginal?
- Three Angels are Dancing on the Head of the Esophageal Cancer Pin, but Shouldn't We Not Topple One or Two?
- MET aberrations and c-MET inhibitors in patients with gastric and esophageal Cancers in a phase I unit.
- Polymorphisms at the microRNA binding-site of the stem cell marker gene CD133 modify susceptibility to and survival of gastric Cancer.
- Genome-wide methylation analysis shows similar patterns in Barrett's esophagus and esophageal adenoCarcinoma.
- Chemoradiation for esophageal Cancer.
- 42. Epigenomic profiling of anal Cancer: does size matter? An RTOG 98-11 specimen study.
- Factors Associated with Local-Regional Failure After Definitive Chemoradiation for Locally Advanced Esophageal Cancer.
- Locoregional Failure Rate After Preoperative Chemoradiation of Esophageal AdenoCarcinoma and the Outcomes of Salvage Strategies.
- ALDH-1 expression levels predict response or resistance to preoperative chemoradiation in resectable esophageal Cancer patients.
- Concordance of studies for nodal staging is prognostic for worse survival in esophageal Cancer.
- Everolimus for Previously Treated Advanced Gastric Cancer: Results of the Randomized, Double-Blind, Phase III GRANITE-1 Study.
- Anal Carcinoma: Impact of TN Category of Disease on Survival, Disease Relapse, and Colostomy Failure in US Gastrointestinal Intergroup RTOG 98-11 Phase 3 Trial.
- Incidence of Brain Metastases after Trimodality Therapy in Patients with Esophageal or Gastroesophageal Cancer: Implications for Screening and Surveillance.
- Gastric Cancer-molecular and clinical dimensions.
- Predictors of postoperative complications after trimodality therapy for esophageal Cancer.
- Association of mitochondrial DNA copy number in peripheral blood leukocytes with risk of esophageal adenoCarcinoma.
- Combination of cisplatin/S-1 in the treatment of patients with advanced gastric or gastroesophageal adenoCarcinoma: Results of noninferiority and safety analyses compa...
- Propensity-Based Matching between Esophagogastric Cancer Patients Who Had Surgery and Who Declined Surgery after Preoperative Chemoradiation.
- Risk assessment of esophageal adenoCarcinoma using γ-H2AX assay.
- Modern oncological approaches to gastric adenoCarcinoma.
- Association between clinical complete response and pathological complete response after preoperative chemoradiation in patients with gastroesophageal Cancer: analysis ...
- Gastric Cancer, Version 2.2013.
- Surgery Is an Essential Component of Multimodality Therapy for Patients with Locally Advanced Esophageal AdenoCarcinoma.
- Obesity and outcomes in patients treated with chemoradiotherapy for esophageal Carcinoma.
- Loss of TGF-? Adaptor ?2SP Activates Notch Signaling and SOX9 Expression in Esophageal AdenoCarcinoma.
- Management of localized gastric Cancer.
- MicroRNA Expression Signatures during Malignant Progression from Barrett's Esophagus to Esophageal AdenoCarcinoma.
- Utilization of surgery in trimodality-eligible patients with locally advanced esophageal adenoCarcinoma in a nonprotocol setting.
- Adjuvant Therapy in Gastric Cancer: What Is The Optimal Approach?
- The role of microRNAs in Cancers of the upper gastrointestinal tract.
- Clinical parameters model for predicting pathologic complete response following preoperative chemoradiation in patients with esophageal Cancer.
- Patients with high body mass index tend to have lower stage of esophageal Carcinoma at diagnosis.
- Salvage Esophagectomy After Failed Definitive Chemoradiation for Esophageal AdenoCarcinoma.
- Propensity Score-based Comparison of Long-term Outcomes With 3-Dimensional Conformal Radiotherapy vs Intensity-Modulated Radiotherapy for Esophageal Cancer.
- A nomogram associated with high probability of malignant nodes in the surgical specimen after trimodality therapy of patients with oesophageal Cancer.
- Chemoradiation: Gastro-oesophageal Cancer-is CROSSing over so hard to do?
- Localized Gastric Cancer Treated with Chemoradation without Surgery: UTMD Anderson Cancer Center Experience.
- Advanced gastroesophageal Carcinoma: an update on the current therapeutic landscape.
- The Crosstalk of mTOR/S6K1 and Hedgehog Pathways.
- Proton Beam Therapy and Concurrent Chemotherapy for Esophageal Cancer.
- Association of Aurora-A (STK15) kinase polymorphisms with clinical outcome of esophageal Cancer treated with preoperative chemoradiation.
- Intensity-modulated radiation therapy with concurrent chemotherapy as preoperative treatment for localized gastric adenoCarcinoma.
- Dual inhibition of Tumor Energy Pathway by 2-deoxy glucose and metformin Is Effective Against a Broad Spectrum of Preclinical Cancer Models.
- Preoperative Chemotherapy for Localized Squamous Cell Carcinoma of the Esophagus? We Should Go Back to the Drawing Board!
- Does the Timing of Esophagectomy After Chemoradiation Affect Outcome?
- Peek before you treat? Is it a fantasy or reality?
- Crescendos and decrescendos: gastric and esophageal Cancers.
- Modern approaches to localized Cancer of the esophagus.
- Esophageal and esophagogastric junction Cancers.
- American Society of Clinical Oncology Clinical Practice Guideline Update on the Use of Chemotherapy Sensitivity and Resistance Assays.
- Update: modern approaches to the treatment of localized esophageal Cancer.
- Celebrate or Calibrate? We Say Calibrate.
- Duplicated Muscularis Mucosae Invasion has Similar Risk of Lymph Node Metastasis and Recurrence-free Survival as Intramucosal Esophageal AdenoCarcinoma.
- Refining docetaxel-containing therapy for gastric Cancer.
- Intrinsic Subtypes of Gastric Cancer, Based on Gene Expression Pattern, Predict Survival and Respond Differently to Chemotherapy.
- A Phase II Study of a Paclitaxel-based Chemoradiation Regimen with Selective Surgical Salvage for Resectable Locoregionally Advanced Esophageal Cancer: Initial Reporti...
- Intensity-Modulated Proton Therapy Further Reduces Normal Tissue Exposure During Definitive Therapy for Locally Advanced Distal Esophageal Tumors: A Dosimetric Study.
- Gene expression signature-based prognostic risk score in gastric Cancer.
- Prognostic significance of baseline positron emission tomography and importance of clinical complete response in patients with Esophageal or gastroEsophageal junction ...
- GCR Graduates From Nursery School on a Fast Track to Editorial ExCellence.
- Combined modality therapy of cT2N0M0 esophageal Cancer: the University of Texas M. D. Anderson Cancer Center experience.
- Prognostic significance of differentially expressed miRNAs in esophageal Cancer.
- The influence of high body mass index on the prognosis of patients with esophageal Cancer after surgery as primary therapy.
- Impact of overall treatment time on survival and local control in patients with anal Cancer: a pooled data analysis of Radiation Therapy Oncology Group trials 87-04 an...
- Esophageal Cancer Dose Escalation using a Simultaneous Integrated Boost Technique.
- Multidisciplinary management of gastric Cancer.
- Critical role of surgery in patients with gastroesophageal Carcinoma with a poor prognosis after chemoradiation as defined by positron emission tomography.
Procedures Preformed
- Cardiac MRI (Magnetic Resonance Imaging) of Heart or Chest
- Thoracentesis
Conditions Treated
- Acute Leukemia
- Adrenal Gland Cancer
- Anemia
- Basal Cell Carcinoma
- View All
Doctors Specialties
- Medical Oncology
- Oncology
Accepted Insurances
Awards
- America's Top Doctors
- Top Doctors:SE Texas
- America's Top Doctors for Cancer
Education
-
University of Texas MD Anderson Cancer Center -
Tulane University -
Indira Gandhi Medical College
Hospital
-
University of Texas M.D. Anderson Cancer Center
Drug Facts
| NPI NUMBER | 1124107156 | |
| NPPES Provider LastName | AJANI | |
| NPPES Provider FirstName | JAFFER | |
| NPPES Provider ZIPCode | 770304009 | |
| NPPES Provider State | TX | |
| Specialty Description | Medical Oncology | |
| Total Claim Count | 209.0 | |
| Distinct Opioid Count | 1.0 | |
| Opioid Claim Count | 25.0 | |
| Percent Opioid Claims | 11.96 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1124107156 |
| Last Name Of The Provider | AJANI |
| First Name Of The Provider | JAFFER |
| View All |
Similar Doctors
|
|
Dr. Merrill S. Kies, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Sattva S. Neelapu, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Jeri Kim, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Banu K. Arun, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Julie A. Ellerhorst, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Sheridan M. Diaz, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Vahid Afsharkharghan, MD
This Doctor is OpenDoctor Recommended.
|